{"id":"c0cb9fc0-57a7-5fb3-a647-fdf2d6d08bf9","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-cox2-makes-the-prostacyclin","predicate":"reduces","statement":"Ibuprofen but not celecoxib significantly inhibited thromboxane-dependent platelet aggregation induced ex vivo by arachidonic acid, 83% against 11.9%, and reduced serum thromboxane B2 by 95% and urinary 11-dehydro thromboxane B2 by 70%, while both ibuprofen and celecoxib suppressed an index of cyclooxygenase-2 activity to a comparable degree and both suppressed urinary excretion of the prostacyclin metabolite 2,3-dinor-6-keto-prostaglandin F1 alpha, data suggesting that cyclooxygenase-2 is a major source of systemic prostacyclin biosynthesis in healthy humans.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"d5124fe5-704d-5e7c-97be-d2930f39f1d7","mechanism_event_label":"The enzyme these drugs are meant to spare the stomach by blocking is the one that makes the body’s main anticlotting prostaglandin.","subject":{"id":"b429f269-1d01-59f4-881a-868de0849d0d","slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"},"object":{"id":"0c85fb2c-861e-57a3-bef3-45598ca98925","slug":"systemic-prostacyclin-biosynthesis","display_name":"Systemic prostacyclin biosynthesis measured as urinary 2,3-dinor-6-keto-prostaglandin F1 alpha","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"d5124fe5-704d-5e7c-97be-d2930f39f1d7","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-cox2-makes-the-prostacyclin-event","event_type":"observed_intervention","label":"The enzyme these drugs are meant to spare the stomach by blocking is the one that makes the body’s main anticlotting prostaglandin.","description":"Ibuprofen but not celecoxib significantly inhibited thromboxane-dependent platelet aggregation induced ex vivo by arachidonic acid, 83% against 11.9%, and reduced serum thromboxane B2 by 95% and urinary 11-dehydro thromboxane B2 by 70%, while both ibuprofen and celecoxib suppressed an index of cyclooxygenase-2 activity to a comparable degree and both suppressed urinary excretion of the prostacyclin metabolite 2,3-dinor-6-keto-prostaglandin F1 alpha, data suggesting that cyclooxygenase-2 is a major source of systemic prostacyclin biosynthesis in healthy humans.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"91dc5902-d7b9-5396-bd6b-d386498804dc","slug":"celecoxib","display_name":"Celecoxib","entity_type_key":"drug"},"role":"comparator_drug","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"c8a31ed4-f2ca-5d43-8352-e9935129a785","slug":"ptgs2","display_name":"Cyclooxygenase-2 (PTGS2)","entity_type_key":"protein"},"role":"prostacyclin_source","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"25063538-7b79-5cd4-9839-511490482e03","slug":"prostacyclin","display_name":"Prostacyclin / prostaglandin I2","entity_type_key":"small_molecule"},"role":"suppressed_mediator","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"3b200ef2-893f-5ca7-93f4-ea657577a760","slug":"thromboxane-b2","display_name":"Thromboxane B2","entity_type_key":"small_molecule"},"role":"co_measured","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"62fb7071-17c2-5dac-9b3a-ee2122708735","slug":"platelet-aggregation-ibu","display_name":"Arachidonic-acid-induced platelet aggregation","entity_type_key":"cellular_process"},"role":"affected_endpoint","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"b429f269-1d01-59f4-881a-868de0849d0d","slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""},{"entity":{"id":"0c85fb2c-861e-57a3-bef3-45598ca98925","slug":"systemic-prostacyclin-biosynthesis","display_name":"Systemic prostacyclin biosynthesis measured as urinary 2,3-dinor-6-keto-prostaglandin F1 alpha","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":6,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ibuprofen-research/9874808.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a643d03df8bc925866696516e7040644634dca29b4f98d39df38ea9c9ab295f4\", \"start_char\": 0, \"end_char\": 1789, \"text_sha256\": \"a643d03df8bc925866696516e7040644634dca29b4f98d39df38ea9c9ab295f4\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Volunteers given celecoxib at three doses or ibuprofen, with platelet, serum and urinary indices","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"800 milligrams ibuprofen against 100, 400 or 800 milligrams celecoxib","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Measures both isoform-specific indices in the same people, which is what allows the prostacyclin source to be assigned. Acute dosing in healthy volunteers.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.","comparator":null,"unit":null,"notes":"","entity":{"slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The enzyme these drugs are meant to spare the stomach by blocking is the one that makes the body’s main anticlotting prostaglandin.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ibu-p9874808] Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. (1999). https://pubmed.ncbi.nlm.nih.gov/9874808/ DOI: 10.1073/pnas.96.1.272","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Platelets and whole body","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"0a97c6b9-3b6d-53d1-b8e5-11641b8627fc","evidence_kind":"source_excerpt","locator":"Lines 526-537","start_line":526,"end_line":537,"excerpt":"### ibu-cox2-makes-the-prostacyclin\nIbuprofen but not celecoxib significantly inhibited thromboxane-dependent platelet aggregation induced ex vivo by arachidonic acid, 83% against 11.9%, and reduced serum thromboxane B2 by 95% and urinary 11-dehydro thromboxane B2 by 70%, while both ibuprofen and celecoxib suppressed an index of cyclooxygenase-2 activity to a comparable degree and both suppressed urinary excretion of the prostacyclin metabolite 2,3-dinor-6-keto-prostaglandin F1 alpha, data suggesting that cyclooxygenase-2 is a major source of systemic prostacyclin biosynthesis in healthy humans.\nCondition category: normal\nnutrient_topic: Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.\nplain_language: The enzyme these drugs are meant to spare the stomach by blocking is the one that makes the body’s main anticlotting prostaglandin.\norganism: Human\ntissue_or_cell_type: Platelets and whole body\nexperimental_model: Volunteers given celecoxib at three doses or ibuprofen, with platelet, serum and urinary indices\nlimitations: Measures both isoform-specific indices in the same people, which is what allows the prostacyclin source to be assigned. Acute dosing in healthy volunteers.\nexposure: 800 milligrams ibuprofen against 100, 400 or 800 milligrams celecoxib\nevidence_span: {\"source_cache\": \"artifacts/ibuprofen-research/9874808.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a643d03df8bc925866696516e7040644634dca29b4f98d39df38ea9c9ab295f4\", \"start_char\": 0, \"end_char\": 1789, \"text_sha256\": \"a643d03df8bc925866696516e7040644634dca29b4f98d39df38ea9c9ab295f4\"}\n[ibu-p9874808] Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. (1999). https://pubmed.ncbi.nlm.nih.gov/9874808/ DOI: 10.1073/pnas.96.1.272","model_system":"Volunteers given celecoxib at three doses or ibuprofen, with platelet, serum and urinary indices","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ibu-p9874808] Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. (1999). https://pubmed.ncbi.nlm.nih.gov/9874808/ DOI: 10.1073/pnas.96.1.272","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"31c4939d-f520-55c0-973b-224743caf245","stable_key":"import-3238e4f0-8d45-5c72-8624-6e9a8b20527c","title":"Ibuprofen: the enantiomer that works, the one that was called inactive, the one-way chemistry that turns one into the other, and the targets that are not cyclooxygenase (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"cc2b388178f97f5906b66ecbe441fc5c86d51fd645947c5260fb0b4bdb4bcd21","revision_id":"0b4e5c65-05d3-5430-a4cd-8d6a03647dcb","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}